Back to Journals » Research and Reports in Urology » Volume 5

New therapeutic targets in the management of urothelial carcinoma of the bladder

Authors Sverrisson, Espiritu, Spiess P

Received 8 December 2012

Accepted for publication 25 January 2013

Published 1 March 2013 Volume 2013:5 Pages 53—65

DOI https://doi.org/10.2147/RRU.S29131

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 6



Video abstract presented by Philippe E Spiess

Views: 508

Einar F Sverrisson, Patrick N Espiritu, Philippe E Spiess

Department of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA

Abstract: Urothelial carcinoma of the bladder, despite the myriad of treatment approaches and our progressively increasing knowledge into its disease processes, remains one of the most clinically challenging problems in modern urological clinical practice. New therapies target biomolecular pathways and cellular mediators responsible for regulating cell growth and metabolism, both of which are frequently overexpressed in malignant urothelial cells, with the intent of inducing cell death by limiting cellular metabolism and growth, creating an immune response, or selectively delivering or activating a cytotoxic agent. These new and novel therapies may offer a potential for reduced toxicity and an encouraging hope for better treatment outcomes, particularly for a disease often refractory or not amenable to the current therapeutic approaches.

Keywords: targeted therapy, intravesical agents, systemic therapies

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.